Background: Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard of care for patients with esophageal or junctional cancer, but the long-term impact of nCRT on health-related quality of life (HRQOL) is unknown. The purpose of this study is to compare very long-term HRQOL in long-term survivors of esophageal cancer who received nCRT plus surgery or surgery alone.
Introduction
Esophageal cancer is characterized by frequent locoregional and distant recurrence. The 5-year overall survival rate rarely exceeds 40% after primary surgery. In order to improve locoregional control and overall survival, neoadjuvant chemo(radio)therapy has been investigated in many clinical trials [1] .
The ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) trial compared a carboplatin and paclitaxel based neoadjuvant chemoradiotherapy (nCRT) regimen plus surgery with surgery alone. Eight centers in the Netherlands participated. After a minimum follow-up of 5 years, a clinically relevant and statistically significant benefit in overall-and progression-free survival rates was shown for the multimodality group. Treatment-related toxicity and postoperative complication rate were acceptable [2, 3] . Based on these results, nCRT followed by surgery according to the CROSS regimen is a standard care in many countries [4] .
The increasing emphasis on patient-reported outcome measures and health-related quality of life (HRQOL) leads to a more prominent role of these measures as end points in clinical trials. Thus far, HRQOL has received limited attention in the field of esophageal cancer, but the wide introduction of nCRT and the associated increased survival emphasize the need for high-quality HRQOL data from these patients. It is known that esophagectomy has profound and lasting impact on patients' HRQOL [5, 6] . The short-term HRQOL analysis of the CROSS trial (followup 1 year) showed that adding nCRT to surgery does not adversely impact postoperative HRQOL [6] , which is in line with results from earlier retrospective studies [7] [8] [9] . However, followup of these studies did not exceed 24 months [6] [7] [8] [9] . Importantly, side-effects of radiotherapy can develop years after treatment, with the lungs being the most radiosensitive organ in the chest [10] . Therefore, long-term HRQOL data from patients treated with nCRT plus surgery are desired.
The aim of this sub-study of the CROSS trial was to compare HRQOL in long-term survivors (>6 years) who received nCRT plus surgery or surgery alone.
Methods
Details of this randomized trial have been reported previously [2, 3] . Briefly, patients with locally advanced (clinical stage T1N1M0 or T2-3N0-1M0, 6th edition of the Union for International Cancer Control TNM cancer staging) [11] esophageal or esophagogastric junctional squamous cell carcinoma or adenocarcinoma were eligible. Patients were randomized between nCRT plus surgery and surgery alone. The study protocol was approved by the ethical committees of the participating centers, and ethical approval for long-term HRQOL measurement was provided by the medical ethical committee of the Erasmus MC. All included patients provided written informed consent.
Procedures
Patients assigned to nCRT were treated with carboplatin (AUC 2 mg/ml/ min) and paclitaxel (50 mg/m 2 of body-surface area) for five weekly cycles. Concomitant radiation therapy was given in 23 fractions of 1.8 Gy (41.4 Gy total). Patients assigned to surgery alone were operated as soon as possible, whereas patients in the nCRT group underwent surgery 4-6 weeks after completion of nCRT. Patients with carcinomas at or above the level of the carina underwent a transthoracic esophagectomy with two-field lymphadenectomy, whereas patients with carcinomas below the carina, either had a transthoracic esophagectomy with twofield lymphadenectomy or had a transhiatal esophagectomy with upper abdominal and lower mediastinal lymphadenectomy, depending on patient characteristics and local preferences. For patients with carcinomas involving the esophagogastric junction, a transhiatal esophagectomy was recommended.
HRQOL measurement
Cancer-specific HRQOL was assessed using the EORTC-QLQ-C30, a validated self-completed questionnaire designed for cancer patients [12] . Tumor-specific HRQOL was assessed using the EORTC-QLQ-OES24 self-completed questionnaire [13] . The EORTC-QLQ-OES24 was used to allow for comparison with baseline and 12 months postoperative questionnaires, as the currently used derivative, EORTC QLQ-OES18, was not available at that time. During long-term follow-up assessment, the K-BILD questionnaire was added to assess pulmonary effects of radiotherapy. The K-BILD is a self-completed validated questionnaire for interstitial lung disease patients [14] .
The self-completed questionnaires were mailed to all patients who were alive after a minimum follow-up of 6 years after surgery. Patients who had not completed the questionnaires within 1 month were reminded two times by telephone. To allow for examination of HRQOL over time, questionnaire scores were compared with pretreatment and 12 months postoperative questionnaire scores from the earlier short-term HRQOL study (follow-up 1 year after surgery) [6] . Before the analysis, end points were predefined by consensus discussion with experienced medical oncologists, upper-GI surgical oncologists and nurse practitioners. End points were defined based on clinical relevance and hypothesized relation with long-term outcome of nCRT. Primary end points were physical functioning (QLQ-C30), eating problems (QLQ-OES24) and total respiratory problems (K-BILD). Secondary end points were global quality of life and fatigue (both QLQ-C30).
Statistical analysis
Patients who were alive during long-term follow-up assessment (July 2015) were included in the analysis. Pretreatment patient characteristics were compared using Student's t-test or Mann-Whitney U test for continuous characteristics, whereas v 2 test or Fisher's exact test was used for comparison of categorical characteristics.
Questionnaire scale scores were transformed into a 0-100 scale as was described previously [14, 15] . Baseline (questionnaire) scores of the two treatment groups were compared using Student's t test. Over-time differential effects between the treatment groups and longitudinal differences of the follow-up measurements were investigated using mixed modeling analysis. If no statistically significant differential effects were found between both groups, results of the combined groups are reported. Mixed modeling allows for inclusion of questionnaires from subjects with different numbers of completed measurements and thereby enables analysis of all available data [16] . Hence, all available questionnaires were included in the analyses. Mean changes between groups and over time differential effects were described. Cohen's d (CD) effect sizes were calculated to assess clinical relevance of the effects and to enable standardized comparison between different outcome variables. CD effect sizes were derived from the b-estimates in the mixed modeling procedure. CD values of 0.2, 0.5 and 0.8 reflect small, medium and large effects, respectively [17] . Values >0.5 indicate clinically relevant effects [18] .
As multiple comparisons correction, P < 0.025 was considered statistically significant for the mixed models analyses (the main analyses included two comparisons and thus a Bonferroni correction of 0.05/2 was applied), whereas P < 0.05 was considered statistically significant for clinical characteristics and baseline score comparisons. All P-values are two-sided. Data were analyzed using SPSS version 21.0.
Results
Of the 368 patients included in the CROSS trial, 123 (33%) were still alive (70 nCRT plus surgery, 53surgery alone). Median follow-up was 105 months. Patients in the nCRT group were older, but there were no other statistically significant differences in pretreatment clinicopathologic characteristics between the groups (Table 1) . The majority of patients was male (76% and 77%, respectively), most patients had an adenocarcinoma (73% and 76%, respectively) and most tumors were clinically staged as cT3 (77% and 76%, respectively). Most patients had suspected locoregional lymph node metastases (54% and 69%, respectively). Due to an administrative error, 32 of the long-term survivors did not receive baseline HRQOL questionnaires. These patients were not excluded from the analysis, because their pretreatment characteristics were not significantly different from the total study group (data not shown), and follow-up questionnaires were correctly mailed and completed [6] .
Overall response rate to the HRQOL questionnaires in the 123 long-term survivors was 89% (Table 2 ). In the nCRT-group response rate was 94%, whereas in the surgery alone group this was 83% (P ¼ 0.07). Mean scores of all HRQOL domains of the EORTC-questionnaires and K-BILD questionnaire are reported in Tables 3 and 4 , respectively.
Primary end points
Pretreatment, there were no statistically significant differences in physical functioning between both groups (P ¼ 0.32). Effects over time were comparable in both groups (P ¼ 0.46). Physical functioning had declined 12 months after surgery compared with baseline (À6, P < 0.001; CD À0.37, 95% CI À0.58 to À 0.16), and stayed stable during long-term follow-up (À3, P ¼ 0.10; CD À0.19, 95% CI À0.42 to 0.04, Figure 1A) .
Baseline eating problems scores and overall changes over time were comparable in both groups (P ¼ 0.52, P ¼ 0.90, respectively). Twelve months postoperatively, eating problems were comparable to baseline (À4, P ¼ 0.24; CD À0.18, 95% CI À0.48 to 0.12) and remained stable after long-term follow-up (À5, P ¼ 0.09; CD À0.20, 95% CI À0.43 to 0.03). Compared with baseline, a significant improvement was reported after long-term follow-up (À9, P ¼ 0.011; CD À0.37, 95% CI À0.66 to À0.09, Figure 1B ).
After long-time follow-up, there were no statistically significant differences in overall respiratory problems between both groups (P ¼ 0.69; CD 0.08, 95%CI À0.32 to 0.48).
Secondary end points
No statistically significant differences in global quality of life were found at baseline (P ¼ 0.35), and no differential effects between both groups over time-up were detected (P ¼ 0.57). One year after surgery, scores were comparable to baseline (þ2, P ¼ 0.56; CD 0.08, 95%CI À0.20 to 0.37) and no statistically significant improvement was found after long-term follow-up compared with 12 months postoperatively (þ2, P ¼ 0.96; CD 0.01, 95%CI À0.24 to 0.26).
Baseline fatigue levels were comparable in both groups (P ¼ 0.60) and all effects over time were comparable between the groups (P ¼ 0.48). One year after surgery, fatigue levels had worsened compared with baseline (þ9, P < 0.001; CD 0.39, 95% CI 0.16-0.62), and remained stable during long-term follow-up (þ2, P ¼ 0.24; CD 0.12, 95%CI À0.08 to 0.31). 
Influence of missing baseline questionnaires
In order to investigate the effect of missing baseline questionnaires, the availability of baseline questionnaires was included as control variable in a separate analysis. This did not influence the described trends in HRQOL trajectory (data not shown).
Discussion
There were no clinically relevant differential effects in HRQOL between long-term survivors of esophageal or esophagogastric junctional cancer treated with nCRT and surgery, compared with surgery alone. In both groups, eating problems improved compared with 1-year postoperative levels, whereas physical functioning, global HRQOL and fatigue remained at the same level. Physical functioning and fatigue were not restored to pretreatment levels and corresponding effect sizes were clinically relevant (CD À0.56 and 0.51, respectively). These results indicate a lasting impact of surgery, regardless of the use of nCRT. Earlier studies have shown that adding nCRT to surgery does not adversely impact postoperative HRQOL. However, most of these studies have been criticized by their non-randomized designs and small sample sizes, which make them prone for selection bias and limit their ability to detect small but potentially clinically relevant differences [7À9]. Methodological strengths of the current study include its randomized design and low attrition rate after long-term follow-up, thereby minimizing the risks of selection and attrition bias. Furthermore, the availability of pretreatment and 1-year postoperative data enabled investigation of change trajectories. Notably, none of the previous studies focused on long-term follow-up [7À9]. Late side-effects of radiotherapy can develop years after initial treatment, with the lungs being the most radiosensitive organ in the chest. Symptomatic radiotherapy-induced pulmonary fibrosis is reported in up to 10% of patients after thoracic radiotherapy. Its incidence depends on the total radiation dose, the irradiated lung volume and the use of chemotherapy. Especially concurrent chemotherapy is associated with an increased incidence of (chemo-)radiotherapy induced pulmonary fibrosis. Symptoms include dyspnea, chest pain, cough, malaise and weight loss, which may exert profound effects on HRQOL, thereby underlining the relevance of effect studies [10] . The finding that adding nCRT to surgery does not adversely impact postoperative HRQOL, confirms the relatively low toxicity of the CROSS regimen [2, 6] . Interestingly, an earlier study found a lasting impairment in physical functioning and dyspnea after chemoradiotherapy, compared with surgery alone. These conflicting results can be explained by the higher dose of radiotherapy (66 Gy) and the more toxic chemotherapeutic agents that were applied in that study (5-FU/cisplatinum) [19] . It should be noted that novel radiotherapy techniques applied in the CROSS trial have likely also reduced therapy-related complications. Besides the improvement in survival, the absent impact on HRQOL is an important argument to apply the CROSS regimen as regimen of first choice [3] .
Although no impact of nCRT on HRQOL was apparent, both treatment groups experienced long-lasting impact of esophagectomy on HRQOL. The reported deterioration in physical functioning and fatigue might also be explained by increasing age. However, studies that used a matched reference population also reported reduced long-term HRQOL [20, 21] . Moreover, pretreatment HRQOL data were obtained after patients had been confronted with the diagnosis of esophageal cancer, when they already were suffering from disease symptoms and were psychologically affected by their recent diagnosis. Consequently, pretreatment HRQOL levels probably represent an underestimation of patients' HRQOL levels before diagnosis, thereby further emphasizing the (negative) impact of esophagectomy.
The lasting deterioration in HRQOL is in line with earlier studies [5, 21, 22] . Our short-term analysis on all included patients showed impaired physical functioning and fatigue 1 year after surgery [6] . The current analysis in long-term survivors shows comparable results, indicating that these symptoms last. This suggests that impairment cannot be attributed to a selected group of patients (e.g. patients with subclinical disease recurrence), as was suggested earlier [20] . A recent study investigated HRQOL in patients who were alive 10 years after surgical treatment. Although these patients underwent primary surgery, results are in line with those of the current study, showing that long-term Table 2 . Patients' eligible for quality-of-life assessment, returning the quality-of-life questionnaire, deceased, not returning the quality-of-life questionnaire because they were too ill or because of random reasons at each measurement point HRQOL remains substantially impaired [21] . These findings not only call for long-term supportive care including long-lasting rehabilitation such as cognitive behavior therapy for patients with lasting fatigue [23] , but also for new treatment strategies with optimal preservation of HRQOL. Definitive chemoradiotherapy without esophagectomy has been evaluated for patients with squamous cell carcinoma. Locoregional recurrence rates and long-term survival were found to be inferior, when compared with (nCRT followed by) surgery. Therefore, definitive chemoradiotherapy with active surveillance and salvage surgery for non-responders is a treatment option [4] . Furthermore, the effects of minimally invasive and hybrid surgical techniques, and an active surveillance strategy after nCRT (23) 81 (21) 90 (16) 78 (24) 87 (20) 80 (24) Symptom scores Fatigue 13 (17) 16 (21) 25 (20) 20 (15) 27 (22) 22 (24) Nausea and vomiting 5 (11) 6 (12) 11 (16) 15 (20) 7 (14) 10 (21) Pain 12 (19) 14 (22) 6 (11) 18 (20) 10 (20) 10 (17) Dyspnea 5 (12) 2 (9) 16 (22) 11 (18) 19 (25) 14 (21) Insomnia 23 (26) 20 (31) 14 (23) 16 (25) 20 (27) 20 (27) Loss of appetite 10 (24) 7 (17) 10 (19) 10 (18) 12 (23) 15 (28) Constipation 8 (19) 1 (6) 8 (20) 11 (20) 10 (17) 5 (12) Diarrhea 2 (11) 0 (0) 16 (24) 18 (23) 16 (24) 17 (26) Financial worries 7 (18) 9 (24) 9 (19) 13 (26) 12 (25) 11 (28) QLQ-OES24
Eating problems 29 (27) 33 (28) 24 (21) 29 (27) 20 (20) 22 ( (25) 48 (18) 29 (20) 33 (23) 29 (22) 25 ( (23) 14 (30) 10 (22) 10 (25) 17 (32) Aspiration 14 (27) 7 (14) 18 (28) 16 (23) 13 (24) 18 ( (instead of standard esophagectomy) on HRQOL should be investigated [24, 25] . Limitations of the current study include its relatively small sample size. This is inevitable in long-term follow-up studies investigating diseases with poor survival. The current study provides the largest available dataset on long-term HRQOL after nCRT, and its sample size has sufficient power to detect clinically relevant differences. Nevertheless, the ability of this dataset to capture long-term complications that are present in a minority of patients is limited. Patients in the nCRT-group were slightly older than patients in the surgery alone group. However, survivors were selected from randomized groups with similar baseline characteristics, suggesting that this difference in age is a result of the experimental treatment (nCRT), rather than of selection bias [2, 3] . Moreover, it does not seem plausible that the higher age has positively influenced HRQOL. Furthermore, patients completed questionnaires at one point in time, which introduced different follow-up times between patients who were included at different time points. However, there were no differences in median follow-up time between both groups and it is unlikely that treatment-related HRQOL still changes substantially after more than 6 years of follow-up. Therefore, we feel that the effect of differences in follow-up duration on HRQOL outcome is negligible. Since this trial included relatively few patients with poor performance status (patients with WHO >2 were excluded) and high age (patients >75 years were also excluded), the results cannot be extrapolated to other categories of more vulnerable patients. The effect of the CROSS regimen on (long term) HRQOL in more vulnerable subgroups of patients remains to be investigated. Finally, the EORTC-QLQ-OES24 has been revised into the EORTC-QLQ-OES18, with refinement of the hypothesized scales and removal of two single items [13] . To allow for comparison with baseline and 12 months postoperative questionnaires, we used the EORTC-QLQ-OES24. We believe that this did not limit the validity of the results, because the eating problems domain was retained in its original form.
In conclusion, no impact of nCRT is apparent on long-term HRQOL compared with surgery alone. In addition to the improvement in long-term survival and the absent impact on postoperative recovery, these results support the view that nCRT can be considered as a standard care for patients with locally advanced esophageal or esophagogastric junctional cancer.
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